---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-052234"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:34:07.705680+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aldeyra completes enrollment in Phase 3 dry eye trial of reproxalap; results expected in Q3 2024

## Summary
- Phase 3 dry eye chamber trial of 0.25% reproxalap enrolled 132 patients; primary endpoint is ocular discomfort.
- Topline results expected in Q3 2024; NDA resubmission planned for H2 2024 contingent on positive data.
- If approved, reproxalap may be first dry eye drug labeling chronic/acute symptom improvement and ocular redness reduction.
- Four prior chamber trials showed reproxalap statistically superior to vehicle on ocular discomfort (p=0.0003).

## SEC filing metadata
- accession: 0001213900-24-052234
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000121390024052234/0001213900-24-052234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000121390024052234/ea0207791-8k_aldeyra.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-052234
- JSON: https://secwatch.observer/filing/0001213900-24-052234.json
- Plain text: https://secwatch.observer/filing/0001213900-24-052234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.